Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib

Several double ALK fusions coexisting in one patient have been reported. However, few studies have reported the clinical efficacy of ALK inhibitors in rare double ALK fusions. Here, we described a rare PDK1-ALK, STRN-ALK double-fusion variant in a patient with metastatic lung adenocarcinoma. The pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Hao, Li, Yalun, Wang, Ye, Huang, Meijuan, Zhang, Yan, Tian, Panwen, Li, Weimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415000/
https://www.ncbi.nlm.nih.gov/pubmed/34485156
http://dx.doi.org/10.3389/fonc.2021.722843
_version_ 1783747888662183936
author Zeng, Hao
Li, Yalun
Wang, Ye
Huang, Meijuan
Zhang, Yan
Tian, Panwen
Li, Weimin
author_facet Zeng, Hao
Li, Yalun
Wang, Ye
Huang, Meijuan
Zhang, Yan
Tian, Panwen
Li, Weimin
author_sort Zeng, Hao
collection PubMed
description Several double ALK fusions coexisting in one patient have been reported. However, few studies have reported the clinical efficacy of ALK inhibitors in rare double ALK fusions. Here, we described a rare PDK1-ALK, STRN-ALK double-fusion variant in a patient with metastatic lung adenocarcinoma. The patient responded well to alectinib (600 mg) twice daily. This case shows a promising treatment option for patients with rare ALK double-fusion variants.
format Online
Article
Text
id pubmed-8415000
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84150002021-09-04 Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib Zeng, Hao Li, Yalun Wang, Ye Huang, Meijuan Zhang, Yan Tian, Panwen Li, Weimin Front Oncol Oncology Several double ALK fusions coexisting in one patient have been reported. However, few studies have reported the clinical efficacy of ALK inhibitors in rare double ALK fusions. Here, we described a rare PDK1-ALK, STRN-ALK double-fusion variant in a patient with metastatic lung adenocarcinoma. The patient responded well to alectinib (600 mg) twice daily. This case shows a promising treatment option for patients with rare ALK double-fusion variants. Frontiers Media S.A. 2021-08-13 /pmc/articles/PMC8415000/ /pubmed/34485156 http://dx.doi.org/10.3389/fonc.2021.722843 Text en Copyright © 2021 Zeng, Li, Wang, Huang, Zhang, Tian and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zeng, Hao
Li, Yalun
Wang, Ye
Huang, Meijuan
Zhang, Yan
Tian, Panwen
Li, Weimin
Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib
title Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib
title_full Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib
title_fullStr Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib
title_full_unstemmed Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib
title_short Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib
title_sort case report: identification of two rare fusions, pdk1-alk and strn-alk, that coexist in a lung adenocarcinoma patient and the response to alectinib
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415000/
https://www.ncbi.nlm.nih.gov/pubmed/34485156
http://dx.doi.org/10.3389/fonc.2021.722843
work_keys_str_mv AT zenghao casereportidentificationoftworarefusionspdk1alkandstrnalkthatcoexistinalungadenocarcinomapatientandtheresponsetoalectinib
AT liyalun casereportidentificationoftworarefusionspdk1alkandstrnalkthatcoexistinalungadenocarcinomapatientandtheresponsetoalectinib
AT wangye casereportidentificationoftworarefusionspdk1alkandstrnalkthatcoexistinalungadenocarcinomapatientandtheresponsetoalectinib
AT huangmeijuan casereportidentificationoftworarefusionspdk1alkandstrnalkthatcoexistinalungadenocarcinomapatientandtheresponsetoalectinib
AT zhangyan casereportidentificationoftworarefusionspdk1alkandstrnalkthatcoexistinalungadenocarcinomapatientandtheresponsetoalectinib
AT tianpanwen casereportidentificationoftworarefusionspdk1alkandstrnalkthatcoexistinalungadenocarcinomapatientandtheresponsetoalectinib
AT liweimin casereportidentificationoftworarefusionspdk1alkandstrnalkthatcoexistinalungadenocarcinomapatientandtheresponsetoalectinib

Ejemplares similares